Nordea Investment Management AB Boosts Stake in Insulet Corporation $PODD

Key Points

• Nordea Investment Management AB increased its stake in Insulet Corporation by 5.7%, owning approximately 389,658 shares valued at $122.38 million as of the latest filing.
• Several institutional investors, including Inspire Investing LLC and Goldman Sachs Group Inc., have significantly increased their holdings in Insulet, indicating positive sentiment among institutional investors.
• Insulet reported a 32.9% year-over-year increase in quarterly revenue, achieving $649.10 million and earnings per share of $1.17, which surpassed analysts' expectations.

Nordea Investment Management AB raised its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 5.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 389,658 shares of the medical instruments supplier's stock after buying an additional 21,064 shares during the quarter. Nordea Investment Management AB owned about 0.55% of Insulet worth $122,384,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Inspire Investing LLC grew its position in Insulet by 299.5% during the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier's stock worth $1,082,000 after buying an additional 3,088 shares in the last quarter. Gradient Investments LLC purchased a new position in Insulet during the second quarter worth about $17,429,000. Goldman Sachs Group Inc. grew its position in Insulet by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier's stock worth $152,130,000 after buying an additional 10,628 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in Insulet by 55.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after buying an additional 1,867 shares in the last quarter. Finally, Vident Advisory LLC purchased a new position in Insulet during the first quarter worth about $216,000.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PODD shares. Morgan Stanley reaffirmed an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. The Goldman Sachs Group dropped their price target on Insulet from $399.00 to $375.00 and set a "buy" rating for the company in a research note on Wednesday, October 1st. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Insulet in a research note on Wednesday, October 8th. Citigroup reaffirmed a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Finally, Barclays lifted their price target on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $348.05.

Insulet Trading Up 0.7%

Shares of PODD stock opened at $318.59 on Friday. The stock has a market capitalization of $22.43 billion, a PE ratio of 96.84, a P/E/G ratio of 2.64 and a beta of 1.40. Insulet Corporation has a 1-year low of $226.50 and a 1-year high of $353.50. The business has a 50-day moving average of $326.22 and a 200 day moving average of $301.98. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Activity

In other Insulet news, SVP Prem Singh sold 687 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the company's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.